|Source||Humanized (from mouse)|
|Trade names||Herclon, Herceptin|
|Metabolism||Unknown, possibly reticuloendothelial system.|
|Biological half-life||2-12 days|
|CAS Registry Number|
|Molecular mass||145531.5 g/mol|
|(what is this?)|
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER proteins stimulate cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.
A 2014 Cochrane Review examined the safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib for the treatment of metastatic breast cancer. The overall hazard ratios for overall survival and progression free survival were 0.82 and 0.61 respectively. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross over and receive trastuzumab after their cancer began to progress. Thus this analysis likely underestimates the true survival benefit associated with trastuzumab treatment in this population. In these trials, trastuzumab also increased the risk of heart problems, including heart failure (RR 3.49) and left ventricular ejection fraction decline (RR 2.65).
In early stage (curable) HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (HR 0.66) and disease-free survival (HR 0.60) relative to comparator arms involving treatment with placebo or chemotherapy. Increased risk of heart failure was (RR 5.11) and decline in left ventricular ejection fraction (RR 1.83) were seen in these trials as well. Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
The original studies of trastuzumab showed that it improved overall survival in late-stage (metastatic) HER2-positive breast cancer from 20.3 to 25.1 months. In early stage HER2-positive breast cancer, it reduces the risk of cancer returning after surgery by an absolute risk of 9.5%, and the risk of death by an absolute risk of 3%; however, it increases serious heart problems by an absolute risk of 2.1%, though the problems may resolve if treatment is stopped.
Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer". The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone.
It is possible to determine the "erbB2 status" of a tumor, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab. It is surprising that although trastuzumab has great affinity for HER2 and high doses can be administered (due to its low toxicity), 70% of HER2+ patients do not respond to treatment. In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27 (Kip1)  as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation.
Duration of treatment
The optimal duration of add-on trastuzumab is currently unknown. One year of treatment is generally accepted based on current clinical trial evidence that demonstrated the superiority of one year treatment over none. However, a small Finnish trial also showed similar improvement with nine weeks of treatment over no therapy. Due to the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the currently accepted practice of treatment for one year. Debate about treatment duration has become a relevant issue for many public health policy makers due to the high financial costs involved in the administration of trastuzumab for a year. Some countries with a taxpayer-funded public health system, such as New Zealand, have opted to fund only nine weeks of adjuvant therapy as a result. Clinical trial data from Roche show that one year of therapy balances efficacy against adverse side effects.
One of the more serious complications of trastuzumab is its effect on the heart, although this is rare. Trastuzumab is associated with cardiac dysfunction in 2-7% of cases which includes congestive heart failure. As a result, regular cardiac screening with either a MUGA scan or echocardiography is commonly undertaken during the trastuzumab treatment period. The decline in ejection fraction appears to be reversible.
Trastuzumab downregulates neuregulin-1 (NRG-1), which is essential for the activation of cell survival pathways in cardiomyocytes and the maintenance of cardiac function. NRG-1 activates the MAPK pathway and the PI3K/AKT pathway as well as focal adhesion kinases (FAK). These are all significant for the function and structure of cardiomyocytes. Trastuzumab can therefore lead to cardiac dysfunction.
Approximately 10% of people are unable to tolerate the drug because of pre-existing heart problems; physicians are balancing the risk of recurrent cancer against the higher risk of death due to cardiac disease in this population. The risk of cardiomyopathy is increased when trastuzumab is combined with anthracycline chemotherapy (which itself is associated with cardiac toxicity).
Women having periods (or whose periods stopped due to chemotherapy) may need to use barrier contraception (such as condoms) while taking trastuzumab, and for at least six months afterwards. This is because of the possibility of harming a developing baby.
Mechanism of action
The HER2 gene (also known as HER2/neu and ErbB2 gene) is amplified in 20-30% of early-stage breast cancers, which makes it overexpress epidermal growth factor (EGF) receptors in the cell membrane. In some types of cancer HER2 may send signals without growth factors arriving and binding to the receptor, making its effect in the cell constitutive; however, trastuzumab is not effective in this case.
The HER2 pathway promotes cell growth and division when it is functioning normally; however when it is overexpressed, cell growth accelerates beyond its normal limits. In some types of cancer the pathway is exploited to promote rapid cell growth and proliferation and hence tumor formation. The EGF pathway includes the receptors HER1 (EGFR), HER2, HER3, and HER4; the binding of EGF to HER is required to activate the pathway. The pathway initiates the MAP Kinase pathway as well as the PI3 Kinase/AKT pathway, which in turn activates the NF-κB pathway. In cancer cells the HER2 protein can be expressed up to 100 times more than in normal cells (2 million versus 20,000 per cell). This overexpression leads to strong and constant proliferative signaling and hence tumor formation. Overexpression of HER2 also causes deactivation of checkpoints, allowing for even greater increases in proliferation.
HER2 extends across the cell membrane, and carries signals from outside the cell to the inside. Signaling compounds called mitogens (specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular domain of the HER family of receptors. Those bound proteins then link (dimerize), activating the receptor. HER2 sends a signal from its intracellular domain, activating several different biochemical pathways. These include the PI3K/Akt pathway and the MAPK pathway. Signals on these pathways promote cell proliferation and the growth of blood vessels to nourish the tumor (angiogenesis).
Normal cell division — mitosis — has checkpoints that keep cell division under control. Some of the proteins that control this cycle are called cdk2 (CDKs). Overexpression of HER2 sidesteps these checkpoints, causing cells to proliferate in an uncontrolled fashion. This is caused by phosphorylation by Akt.
Trastuzumab binds to domain IV of the extracellular segment of the HER2/neu receptor. Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there is reduced proliferation. It has been suggested that trastuzumab induces some of its effect by downregulation of HER2/neu leading to disruption of receptor dimerization and signaling through the downstream PI3K cascade. In addition, trastuzumab suppresses angiogenesis both by induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of HER2/neu that results in the release of the extracellular domain. One of the most relevant proteins that trastuzumab activates is the tumor suppressor p27 (kip1), also known as CDKN1B. Trastuzumab activates p27 by simultaneously inhibiting PI3K/Akt, Mirk, hKIS, pathways Trastuzumab has been shown to inhibit HER2/neu ectodomain cleavage in breast cancer cells.
Experiments in laboratory animals indicate that antibodies, including trastuzumab, when bound to a cell, induce immune cells to kill that cell, and that such antibody-dependent cell-mediated cytotoxicity is another important mechanism of action.
There may be other undiscovered mechanisms by which trastuzumab induces regression in cancer.
Trastuzumab inhibits the effects of overexpression of HER2. If the breast cancer doesn't overexpress HER2, trastuzumab will have no beneficial effect (and may cause harm). Doctors use laboratory tests to discover whether HER2 is overexpressed. In the routine clinical laboratory, the most commonly employed methods for this are immunohistochemistry (IHC) and either silver, chromogenic or fluorescent in situ hybridisation (SISH/CISH/FISH). HER2 amplification can be detected by virtual karyotyping of formalin-fixed paraffin embedded tumor. Virtual karyotyping has the added advantage of assessing copy number changes throughout the genome, in addition to detecting HER-2 amplification (but not overexpression). Numerous PCR-based methodologies have also been described in the literature. It is also possible to estimate HER2 copy number from microarray data.
There are two FDA-approved commercial kits available for HER2 IHC; Dako HercepTest and Ventana Pathway. These are highly standardised, semi-quantitative assays which stratify expression levels into; 0 (<20,000 receptors per cell, no visible expression), 1+ (~100,000 receptors per cell, partial membrane staining, < 10% of cells overexpressing HER-2), 2+ (~500,000 receptors per cell, light to moderate complete membrane staining, > 10% of cells overexpressing HER-2), and 3+ (~2,000,000 receptors per cell, strong complete membrane staining, > 10% of cells overexpressing HER-2). The presence of cytoplasmic expression is disregarded. Treatment with trastuzumab is indicated in cases where HER2 expression has a score of 3+. However, IHC has been shown to have numerous limitations, both technical and interpretative, which have been found to impact on the reproducibility and accuracy of results, especially when compared with ISH methodologies. It is also true, however, that some reports have stated that IHC provides excellent correlation between gene copy number and protein expression.
Fluorescent in situ hybridization (FISH) is viewed as being the “gold standard” technique in identifying patients who would benefit from trastuzumab, but it is expensive and requires fluorescence microscopy and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies of CISH and FISH have shown that these two techniques show excellent correlation. The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH. As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail  developed by Ventana Medical Systems. The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section. The detection can be achieved by using a combination of ultraView SISH(silver in-situ hybridization) and ultraView Red ISH for deposition of distinct chromgenic precipitates at the site of DNP or DIG labeled probes.
Currently the recommended assays are a combination of IHC and FISH, whereby IHC scores of 0 and 1+ are negative (no trastuzumab treatment), scores of 3+ are positive (trastuzumab treatment), and score of 2+ (equivocal case) is referred to FISH for a definitive treatment decision. Industry best practices indicate the use of FDA-cleared Automated Tissue Image Systems by laboratories for automated processing of specimens, thereby reducing process variability, avoiding equivocal cases, and ensuring maximum efficacy of trastuzumab therapy.
One of the challenges in the treatment of breast cancer patients by herceptin is our understanding towards herceptin resistance. In the last decade, several assays have been performed to understand the mechanism of Herceptin resistance with/without supplementary drugs. Recently, all this information has been collected and compiled in form of a database HerceptinR. This database HerceptinR is a collection of assays performed to test sensitivity or resistance of Herceptin Antibodies towards breast cancer cell lines. This database provides comprehensive information about experimental data perform to understanding factors behind herceptin resistance as well as assays performed for improving Herceptin sensitivity with the help of supplementary drugs. This is the first database developed to understand herceptin resistance that can be used for designing herceptin sensitive biomarkers.
The biotech company Genentech developed trastuzumab jointly with UCLA and gained FDA approval in September 1998. The drug was first discovered by scientists including Dr. Axel Ullrich and Dr. H. Michael Shepard. At UCLA's Jonsson Comprehensive Cancer Center, Dr. Dennis Slamon subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called Living Proof, that premiered in 2008.
Trastuzumab costs about US$70,000 for a full course of treatment, Trastuzumab brought in $327 million in revenue for Genentech in the fourth quarter of 2007.
Australia has negotiated a lower price of A$50,000 per course of treatment.
Since October 2006 trastuzumab has been made available for Australian women and men with early stage breast cancer via the Pharmaceutical Benefits Scheme. This is estimated to cost the country over A$470 million for 4–5 years supply of the drug.
Roche has changed the trade name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS 75,000 INR ($1,200 USD) in the Indian market.Biocon Ltd, announced on 26 November 2013 that it has received Marketing Authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer. The regulatory approval for biosimilar Trastuzumab in India is the world’s first biosimilar version of Herceptin® to be brought to the market. The biosimilar Trastuzumab will be marketed in India under the brand name of CANMAb™ by Biocon and is expected to be available to Indian patients in Q4 FY14.
- Hudis, CA (2007). "Trastuzumab--mechanism of action and use in clinical practice". N Engl J Med. 357 (1): 39–51. doi:10.1056/NEJMra043186. PMID 17611206. Jul 5;357(1):39-51. Review /article
- Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L et al. (2014). "Trastuzumab-containing regimens for metastatic breast cancer". Cochrane Database Syst Rev 6: CD006242. doi:10.1002/14651858.CD006242.pub2. PMID 24919460.
- "Editorial - Treating metastatic breast cancer: the evidence for targeted therapy | Cochrane Library".
- Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al. (2012). "Trastuzumab containing regimens for early breast cancer". Cochrane Database Syst Rev 4: CD006243. doi:10.1002/14651858.CD006243.pub2. PMID 22513938.
- "www.who.int" (PDF).
- Moja L, Tagliabue L, Balduzzi S et al. (2012). "Trastuzumab containing regimens for early breast cancer". Cochrane Database Syst Rev 4: CD006243. doi:10.1002/14651858.CD006243.pub2. PMID 22513938.
- Tan, AR; Swain SM (2002). "Ongoing adjuvant trials with trastuzumab in breast cancer". Seminars in Oncology 30 (5 Suppl 16): 54–64. doi:10.1053/j.seminoncol.2003.08.008. PMID 14613027.
- Nahta, R; Esteva1 FJ (2003). "HER-2-Targeted Therapy –Lessons Learned and Future Directions". Clinical Cancer Research 9 (14): 5078–5048. PMID 14613984.
- Yu, D; Hung M (2000). "Overexpression of ErbB2 in cancer and ErbB2-targeting strategies". Oncogene 19 (53): 6115–6121. doi:10.1038/sj.onc.1203972. PMID 11156524.
- XF Le, Franz Pruefer, Robert Bast. (2005). "HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways". Cell Cycle 4 (1): 87–95. doi:10.4161/cc.4.1.1360. PMID 15611642.
- Kute, T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP (2004). "Development of Herceptin resistance in breast cancer cells". Cytometry 57A (2): 86–93. doi:10.1002/cyto.a.10095. PMID 14750129.
- Romond, EH; Perez EA; Bryant J et al. (2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". New England Journal of Medicine 353 (16): 1673–1684. doi:10.1056/NEJMoa052122. PMID 16236738.
- Piccart-Gebhart MJ, MJ; Procter M; Leyland-Jones B et al. (2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". New England Journal of Medicine 353 (16): 1659–1672. doi:10.1056/NEJMoa052306. PMID 16236737.
- Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006). "Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer". N Engl J Med 354 (8): 809–20. doi:10.1056/NEJMoa053028. PMID 16495393.
- Metcalfe, S; Evans J; Priest G. (2007). "PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer". N Z Med J 120 (1256): 1U2593. PMID 17589560.
- "Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer". Roche. Retrieved 2013-01-06.
- "View - European Society for Medical Oncology". ESMO. Retrieved 2013-01-06.
- "Breast Cancer Care Trastuzumab factsheet" (PDF). Breast Cancer Care. Retrieved 22 October 2013.
- Seidman, A et al. (2002). "Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience". Journal of Clinical Oncology 20 (5): 1215–1221. doi:10.1200/JCO.20.5.1215. PMID 11870163.
- van Hasselt et al. (2011). "Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity". Clin Pharmacol Ther 90 (1): 126–32. doi:10.1038/clpt.2011.74. PMID 21633346.
- Zeglinski, M., Ludke, A., Jassal, D. S. & Singal, P. K. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp. Clin. Cardiol. 16, 70-74 (2011)
- "Breast Cancer Care Trastuzumab factsheet" (PDF). Retrieved 22 October 2013.
- Bange, J; Zwick E; Ullrich A. (2001). "Molecular targets for breast cancer therapy and prevention". Nature Medicine 7 (5): 548–552. doi:10.1038/87872. PMID 11329054.
- "Targeted Therapies for Breast Cancer Tutorial". National Cancer Institute. Retrieved 19 April 2011.
- Feldman, A M; Koch, W J; Force, T L (28 March 2007). "Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences". Clinical Pharmacology & Therapeutics 81 (6): 887–892. doi:10.1038/sj.clpt.6100160.
- Winer, Eric. "HER2 Disease in the Metastatic and Adjuvant Settings". Medscape Education. Retrieved 20 April 2011.
- Ménard, S; Pupa SM; Campiglio M; Tagliabue E (2003). "Biologic and therapeutic role of HER2 in cancer". Oncogene 22 (42): 6570–6578. doi:10.1038/sj.onc.1206779. PMID 14528282.
- Albanell, J; Codony J; Rovira A; Mellado B; Gascon P. (2003). "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4". Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology 532: 253–268. doi:10.1007/978-1-4615-0081-0_21. ISBN 978-0-306-47762-1. PMID 12908564.
- Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV (2000). "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets". Nat Med 6 (4): 443–6. doi:10.1038/74704. PMID 10742152.
- Jennings, B; Hadfield JE; Worsley SD; Girling A; Willis G. (1997). "A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer.". Molecular Pathology 50 (5): 254–256. doi:10.1136/mp.50.5.254. PMC 379641. PMID 9497915.
- Curtis, C; Shah, SP; Chin, SF; Turashvili, G; Rueda, OM; Dunning, MJ; Speed, D; Lynch, AG; Samarajiwa, S; Yuan, Y; Gräf, S; Ha, G; Haffari, G; Bashashati, A; Russell, R; McKinney, S; METABRIC, Group; Langerød, A; Green, A; Provenzano, E; Wishart, G; Pinder, S; Watson, P; Markowetz, F; Murphy, L; Ellis, I; Purushotham, A; Børresen-Dale, AL; Brenton, JD; Tavaré, S; Caldas, C; Aparicio, S (18 April 2012). "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.". Nature 486 (7403): 346–52. doi:10.1038/nature10983. PMID 22522925.
- "ventanamed.com". ventanamed.com. 2012-05-25. Retrieved 2013-06-16.
- "Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients". BioPortfolio.com. 2011-06-14. Retrieved 2013-01-06.
- "Dual color dual hapten HER2 genotyping for breast biopsy specimens (DDISH): Concordance with fluorescence in situ hybridization (FISH)". ASCO. 2009-10-06. Retrieved 2013-01-06.
- Ahmad S (2014). "Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients". Nature 4.
- "cancer.ucla.edu". cancer.ucla.edu. Retrieved 2013-06-16.
- Fleck L (2006). "The costs of caring: Who pays? Who profits? Who panders?". Hastings Cent Rep 36 (3): 13–7. doi:10.1353/hcr.2006.0040. PMID 16776017.
- "Listing of Herceptin on PBS". Australian Government, Dept of Health and Ageing. 2006-10-01.
- Australian Government, Dept of Health and Ageing "Listing of Herceptin on PBS", 2006-10-1. http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin
- "Emcure signs deal to manufacture Roche's anti-cancer drugs". The Times Of India. 2012-03-02.
- Bazell, Robert. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998. 214 pages. ISBN 0-679-45702-X.
- The Guardian. The selling of a wonder drug. 29 March 2006
- Dent, S; Verma Sh, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K (2009). "The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer". Curr Oncol 16 (4): 25–35. doi:10.3747/co.v16i4.469. PMC 2722050. PMID 19672422. Free full-text article
|Look up trastuzumab in Wiktionary, the free dictionary.|